COVID-19 Respiratory Infection, COVID-19 Vaccine Adverse Reaction
Conditions
Keywords
Covid-19, DNA vaccine, booster dose, in vivo electroporation, adverse reactions, antibody levels, cellular immune response
Brief summary
This is a randomized, placebo-controlled, double-blinded phase I study, designed to evaluate the safety including reactogenicity and immunogenicity of this investigational DNA vaccine delivered intramuscularly by in vivo EP in human adults. The vaccine doses will be given to healthy adults aged 18 to 60 years, who have been previously vaccinated against COVID-19 with 3 doses of either Comirnaty® or Spikevax®, or both in any combination ≥3 months ago.
Detailed description
One dose of the investigational vaccine or placebo will be given as a fourth booster dose. The vaccine will be administered intramuscularly at 3 dose levels or given as placebo (containing a 0.9 % NaCl solution), in combination with in vivo EP. The EP method used in the study is a class IIa EPS Gun from IGEA optimized for Electro Gene Transfer (EGT) vaccination and CE marked for the intended use in this clinical trial. Primary objective: • The primary objective of this study is to assess the safety and reactogenicity of the investigational vaccine OC-007 DNA delivered by in vivo EP, as a booster dose given at ≥ 3 months post-initial mRNA vaccination. The secondary objectives: • To investigate the humoral immune response to the investigational vaccine administered as one dose, by measuring changes in spike and of nucleocapsid antibody levels. Exploratory objective: * To investigate in more detail the humoral response and analyze the cellular immune response to the investigational vaccine * To evaluate the number of SARS-CoV-2 infections documented by positive PCR test during the study period.
Interventions
BIOLOGICALDNA vaccine OC-007
Plasmid DNA vaccine
OTHERPlacebo
0.9% NaCl solution
Sponsors
Matti Sällberg
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double-blinding: subjects, study personnel and outcome assessors are blinded to treatment.
Intervention model description
Randomized, placebo-controlled, double-blinded phase I study including three dose levels of the DNA vaccine OC-007.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Men and women between the ages of 18 and 60 years (at the time of consent). 2. All study subjects have received three doses of registered mRNA vaccine/s, the last dose given ≥ 3 months before inclusion in this study. 3. Healthy participant, according to the investigator's clinical judgment, as established by medical history, vital signs, physical examination, and laboratory assessments. 4. No clinically significant laboratory abnormalities as determined by the investigator at screening. Note: one retest of lab tests is allowed within the screening window. 5. Negative HIV 1/2 antibody/antigen test, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody at screening. 6. Participant with a body mass index (BMI) 20-30.0 kg/m2. 7. Provide written informed consent before initiation of any study procedures. 8. A female participant is eligible for this study if she is one of the following: * of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year) * of childbearing potential but agrees to practice highly effective contraception or abstinence (if this is the preferred and usual lifestyle of the participant) from 30 days prior to vaccination up to 3 months after vaccination. Highly effective methods of contraception include one or more of the following: 1. male partner who is sterile (vasectomised) prior to the female study subject's entry into the study and is the sole sexual partner for the female subject; 2. hormonal (oral, intravaginal, transdermal, implantable or injectable) 3. an intrauterine hormone-releasing system (IUS) 4. an intrauterine device (IUD) with a documented failure rate of \< 1%. 9. A female participant is eligible if she is willing to abstain from donating oocyte from the screening visit up to 3 months after vaccination. 10. A male participant who is sexually active is eligible if he is willing to use a condom from the screening visit up to 3 months after vaccination except if the male participant is sterile (e.g. vasectomised); the unique female sexual partner is postmenopausal, is permanently sterilized (e.g. hysterectomy or tubal ligation), or use a highly effective method of contraception. 11. Able to understand and comply with planned study procedures and willing to be available for all study-required procedures, visits and calls for the duration of the study.
Exclusion criteria
1. Previous vaccination with investigational or registered non-mRNA vaccines against COVID-19. 2. History of presence of pulmonary disorders (chronic obstructive pulmonary lung disease etc) or asthma (exception of allergic asthma, which is allowed). 3. History or presence of thrombocytopenia and/or bleeding disorders. 4. A positive serum pregnancy test at screening or urine pregnancy test prior to study injection, women who are planning to become pregnant during the study, or women who are breastfeeding. 5. Clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory, autoimmune, central nervous system or neurological diseases. 6. Use of immunosuppressive drugs as e.g. corticosteroids (excluding topical preparations and inhalers) within 3 months prior to vaccination or 6 months for chemotherapies and all along the study. 7. Vaccination within 2 weeks prior to vaccination or planning to receive a licensed vaccine before month 3 (e.g. inactivated influenza vaccine). 8. History of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of known or suspected allergic reaction likely to be exacerbated by any component of the Investigational vaccine. 9. Participation in another investigational clinical study within four weeks before the screening visit or planned before the study completion. 10. Subjects with confirmed or suspected immunodeficiency. 11. SARS-CoV-2 infection within the past 2 weeks3 months prior to enrolment, or ongoing symptom of COVID-19. 12. Any condition that in the opinion of the principal investigator (PI) would jeopardize the safety or rights of a person participating in the trial or would render the person unable to comply with the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serious Adverse Events (SAEs)/SUSARs | From the study dose until the study end at 3 months after vaccination. | Serious Adverse Events (SAEs)/suspected unexpected serious adverse reactions (SUSARs) from the study dose until the study end at 3 months after vaccination. |
| Visual analogue scale pain rating scale score | At 0, 5, 15, 30 and 60 minutes post-EP. | Visual analogue scale (VAS) score to rate the level of pain experienced immediately (0 minutes), and after 5, 15, 30 and 60 minutes post-EP. Scale is continous and the farther right on the scale line the more pain. |
| Systemic events for 7 days after each vaccine/placebo dose. | For 7 days after each vaccine/placebo dose. | Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain) for 7 days after each vaccine/placebo dose. |
| Unsolicited AEs | From the study dose to 28 days after vaccination. | Unsolicited AEs from the study dose to 28 days after vaccination. |
| Local reactions after the vaccine/placebo dose | Up to 7 days after the vaccine/placebo dose | Local reactions (pain at the injection site, redness, and swelling) for up to 7 days after the vaccine/placebo dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in antibody levels to the SARS-CoV-2 spike and nucleocapsid protein. | Day 7, Day 14, 1 Month and 3 Months. | Change from baseline sample (a two-fold increase in endpoint titer or a 50% increase in optical density at a 1:62, 1:125, 1:250, 1:500, or 1:1000 serum dilution) in antibody levels to the SARS-CoV-2 spike and nucleocapsid protein by inhouse and/or commercial assays during the study period. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory: SARS-CoV-2 infections | Up to 3 Months | Number and severity of SARS-CoV-2 infections during the study period. |
| Exploratory: In depth humoral and cellular immunological responses | Day 7, Day 14, 1 Month and 3 Months | Description of in depth humoral and cellular immunological responses after receiving investigational vaccine at each sampling. Immunoglobulin levels analysed by Enzyme-Linked Immunosorbent Assays (ELISAs). Antibody titer analysed by CPE based microneutralization assay. Isolated Peripheral Blood Mononuclear Cell behavior analysed by enzyme-linked immunospot (ELISpot) assay. Flow cytometry will be used for functional and phenotypic characterization of T-cells. |
Countries
Sweden
Outcome results
None listed